Zeynep Pınar Önen

RETRACTED: Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Hossein Ardeschir Ghofrani, Gérald Simonneau, Andrea Maria D’Armini et al. · The Lancet Respiratory Medicine · 2017 · 262 citations

Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis

Banu Eriş Gülbay, Özlem Ural Gürkan, Öznur Akkoca Yıldız et al. · Respiratory Medicine · 2006 · 157 citations · Full text

Initial Phase, Pulmonary Tuberculosis, Tuberculosis Prevention +8

Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial

Marius M. Hoeper, Hikmet Al‐Hiti, Raymond L. Benza et al. · The Lancet Respiratory Medicine · 2021 · 151 citations

Hypertension, Pulmonary Arterial Hypertension, Phosphodiesterase-5 Inhibitors +11

Analysis of the factors related to mortality in patients with bronchiectasis

Zeynep Pınar Önen, Banu Eriş Gülbay, Elif Şen et al. · Respiratory Medicine · 2007 · 120 citations · Full text

Epidemiology, Advanced Lung Disease, Clinical Epidemiology +6

Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Hossein Ardeschir Ghofrani, Gérald Simonneau, Andrea Maria D’Armini et al. · The Lancet Respiratory Medicine · 2024 · 31 citations

Thrombosis, Hypertension, Pulmonary Arterial Hypertension +9